1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Gouty Arthritis (Gout) - Pipeline Review, H1 2016

Gouty Arthritis (Gout) - Pipeline Review, H1 2016

  • May 2016
  • -
  • Global Markets Direct
  • -
  • 116 pages

Gouty Arthritis (Gout) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Gouty Arthritis (Gout) - Pipeline Review, H1 2016’, provides an overview of the Gouty Arthritis (Gout) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout)
- The report reviews pipeline therapeutics for Gouty Arthritis (Gout) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Gouty Arthritis (Gout) therapeutics and enlists all their major and minor projects
- The report assesses Gouty Arthritis (Gout) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Gouty Arthritis (Gout)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Gouty Arthritis (Gout) - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Gouty Arthritis (Gout) Overview 10
Therapeutics Development 11
Pipeline Products for Gouty Arthritis (Gout) - Overview 11
Pipeline Products for Gouty Arthritis (Gout) - Comparative Analysis 12
Gouty Arthritis (Gout) - Therapeutics under Development by Companies 13
Gouty Arthritis (Gout) - Therapeutics under Investigation by Universities/Institutes 16
Gouty Arthritis (Gout) - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Gouty Arthritis (Gout) - Products under Development by Companies 21
Gouty Arthritis (Gout) - Products under Investigation by Universities/Institutes 23
Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development 24
AstraZeneca Plc 24
Celtaxsys, Inc. 25
CymaBay Therapeutics, Inc. 26
Delenex Therapeutics AG 27
Immune Response BioPharma, Inc. 28
IOmet Pharma 29
JW Pharmaceutical Corporation 30
LG Life Science LTD. 31
Monosol Rx, LLC 32
Nimbus Therapeutics, LLC 33
Opsona Therapeutics Limited 34
Polaris Pharmaceuticals, Inc. 35
ProteoThera, Inc. 36
Swedish Orphan Biovitrum AB 37
Takeda Pharmaceutical Company Limited 38
Teijin Pharma Limited 39
TWi Pharmaceuticals, Inc. 40
Wellstat Therapeutics Corporation 41
Gouty Arthritis (Gout) - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
acebilustat - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
anakinra (recombinant) - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
APP-112 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
arhalofenate - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
AXIBU-03 - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
colchicine - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
diacerein - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
DLX-2323 - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
DLX-2681 - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
febuxostat - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
febuxostat XR - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
IR-888 - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
LC-350189 - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation and Neurodegenerative Diseases - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
ND-2110 - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
ND-2158 - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
ND-346 - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
pegadricase - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
PRT-1000 - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
Recombinant Enzyme for Gout and Tumor Lysis Syndrome - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
REV-002 - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
RLBN-1001 - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
RLBN-2020 Series - Drug Profile 81
Product Description 81
Mechanism of Action 81
RandD Progress 81
RLBN-3010 Series - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
Small Molecule Inflammasome Modulator Programme - Drug Profile 83
Product Description 83
Mechanism of Action 83
RandD Progress 83
Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile 84
Product Description 84
Mechanism of Action 84
RandD Progress 84
Small Molecules to Inhibit GLUT9 for Gout - Drug Profile 85
Product Description 85
Mechanism of Action 85
RandD Progress 85
TMX-049 - Drug Profile 86
Product Description 86
Mechanism of Action 86
RandD Progress 86
URC-102 - Drug Profile 87
Product Description 87
Mechanism of Action 87
RandD Progress 87
uriSHELS - Drug Profile 88
Product Description 88
Mechanism of Action 88
RandD Progress 88
verinurad - Drug Profile 89
Product Description 89
Mechanism of Action 89
RandD Progress 89
WT-2107 - Drug Profile 90
Product Description 90
Mechanism of Action 90
RandD Progress 90
XEN-102 - Drug Profile 91
Product Description 91
Mechanism of Action 91
RandD Progress 91
XEN-104 - Drug Profile 92
Product Description 92
Mechanism of Action 92
RandD Progress 92
Gouty Arthritis (Gout) - Recent Pipeline Updates 93
Gouty Arthritis (Gout) - Dormant Projects 104
Gouty Arthritis (Gout) - Discontinued Products 106
Gouty Arthritis (Gout) - Product Development Milestones 107
Featured News and Press Releases 107
Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra) 107
Mar 28, 2016: CymaBay Therapeutics Announces Acceptance of Arhalofenate Phase 2b Gout Study Manuscript in Arthritis and Rheumatology 107
Mar 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra) 108
Jan 20, 2016: CymaBay Therapeutics Announces Successful Completion of End-of-Phase 2 Discussions With FDA for Arhalofenate 109
Dec 24, 2015: TWi Biotechnology Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients 110
Dec 23, 2015: Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial of SEL-212, Designed to be the First Non-Immunogenic Biologic Treatment for Gout 110
Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11 111
Oct 19, 2015: MonoSol Rx Leadership Presents Data Supporting PharmFilm Technology Effective for Oral Peptide Delivery 112
Sep 30, 2015: Revive Therapeutics Announces Positive Interim Results From Phase 2a Study of REV-002 in the Treatment of Acute Gout Flares 113
Aug 06, 2015: CymaBay Strengthens the Intellectual Property of Arhalofenate With Issuance of Two New Patents 114
Appendix 115
Methodology 115
Coverage 115
Secondary Research 115
Primary Research 115
Expert Panel Validation 115
Contact Us 115
Disclaimer 116

List of Tables
Number of Products under Development for Gouty Arthritis (Gout), H1 2016 11
Number of Products under Development for Gouty Arthritis (Gout) - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Development by Companies, H1 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Development, H1 2016 19
Comparative Analysis by Unknown Stage Development, H1 2016 20
Products under Development by Companies, H1 2016 21
Products under Development by Companies, H1 2016 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2016 23
Gouty Arthritis (Gout) - Pipeline by AstraZeneca Plc, H1 2016 24
Gouty Arthritis (Gout) - Pipeline by Celtaxsys, Inc., H1 2016 25
Gouty Arthritis (Gout) - Pipeline by CymaBay Therapeutics, Inc., H1 2016 26
Gouty Arthritis (Gout) - Pipeline by Delenex Therapeutics AG, H1 2016 27
Gouty Arthritis (Gout) - Pipeline by Immune Response BioPharma, Inc., H1 2016 28
Gouty Arthritis (Gout) - Pipeline by IOmet Pharma, H1 2016 29
Gouty Arthritis (Gout) - Pipeline by JW Pharmaceutical Corporation, H1 2016 30
Gouty Arthritis (Gout) - Pipeline by LG Life Science LTD., H1 2016 31
Gouty Arthritis (Gout) - Pipeline by Monosol Rx, LLC, H1 2016 32
Gouty Arthritis (Gout) - Pipeline by Nimbus Therapeutics, LLC, H1 2016 33
Gouty Arthritis (Gout) - Pipeline by Opsona Therapeutics Limited, H1 2016 34
Gouty Arthritis (Gout) - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 35
Gouty Arthritis (Gout) - Pipeline by ProteoThera, Inc., H1 2016 36
Gouty Arthritis (Gout) - Pipeline by Swedish Orphan Biovitrum AB, H1 2016 37
Gouty Arthritis (Gout) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 38
Gouty Arthritis (Gout) - Pipeline by Teijin Pharma Limited, H1 2016 39
Gouty Arthritis (Gout) - Pipeline by TWi Pharmaceuticals, Inc., H1 2016 40
Gouty Arthritis (Gout) - Pipeline by Wellstat Therapeutics Corporation, H1 2016 41
Assessment by Monotherapy Products, H1 2016 42
Number of Products by Stage and Target, H1 2016 44
Number of Products by Stage and Mechanism of Action, H1 2016 46
Number of Products by Stage and Route of Administration, H1 2016 48
Number of Products by Stage and Molecule Type, H1 2016 50
Gouty Arthritis (Gout) Therapeutics - Recent Pipeline Updates, H1 2016 93
Gouty Arthritis (Gout) - Dormant Projects, H1 2016 104
Gouty Arthritis (Gout) - Dormant Projects (Contd..1), H1 2016 105
Gouty Arthritis (Gout) - Discontinued Products, H1 2016 106

List of Figures
Number of Products under Development for Gouty Arthritis (Gout), H1 2016 11
Number of Products under Development for Gouty Arthritis (Gout) - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Products, H1 2016 19
Assessment by Monotherapy Products, H1 2016 42
Number of Products by Top 10 Targets, H1 2016 43
Number of Products by Stage and Top 10 Targets, H1 2016 43
Number of Products by Top 10 Mechanism of Actions, H1 2016 45
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 45
Number of Products by Routes of Administration, H1 2016 47
Number of Products by Stage and Routes of Administration, H1 2016 47
Number of Products by Molecule Types, H1 2016 49
Number of Products by Stage and Molecule Types, H1 2016 49

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region (Asia-Pacific, Others)-Forecast (2016-2021)

Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region (Asia-Pacific, Others)-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Systemic lupus erythematosus, also commonly known as lupus, is an autoimmune disease which results in inflammation of tissues in the body with common symptoms like fever, fatigue, skin rashes, malaise, ...

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Osteoarthritis in 9 Major Markets Osteoarthritis (OA), also known as degenerative joint disease / degenerative arthritis, is an inflammation ...

Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022- Industry Insights by Drug Class

Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022- Industry Insights by Drug Class

  • $ 5100
  • Industry report
  • November 2016
  • by P&S Market Research

The global osteoporosis drugs market was worth $8,835.4 million in 2015 and it is expected to grow at a CAGR of 3.8% during 2016-2022. Among the various drug classes, the rank ligand inhibitors segment ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.